Brainstorm Cell Therapeutics BCLI Cash Flow Statement (2010-2026)

OTC BCLI
$0.77 -0.02 (-2.53%)
As of: Oct 21, 2026 · 11:49 AM EDT
Reported Financials

Brainstorm Cell Therapeutics Quarterly Cash Flow Statement

Periods 65 quarters
Latest Jun 2026

Brainstorm Cell Therapeutics reported cash from operations of -$0.90M and free cash flow of -$0.90M for the quarter ended Jun 2026, up 74.4% year over year. This cash flow statement covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-5.34M-6.19M-5.36M-7.04M-6.86M-5.02M-5.06M-5.33M-1.23M-5.58M-3.40M-2.54M-2.71M-2.97M-2.86M-2.90M-2.11M-2.43M-2.13M-3.86M
Depreciation and DepletionDep. & Depletion
0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.06M0.06M0.06M0.05M0.05M0.05M0.05M0.05M0.04M0.05M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.07M0.06M0.06M0.06M0.05M0.05M0.05M0.05M0.05M0.04M0.05M
Share-based CompensationStock Comp.
0.20M0.64M0.51M0.41M0.40M0.38M0.00M0.99M0.55M-0.05M0.17M0.19M0.18M0.21M0.72M0.50M0.16M0.14M0.13M2.24M
Other non-cash itemsOther Non-Cash
-4.76M0.24M-0.94M0.41M0.39M0.28M-0.18M0.36M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.52M0.91M-0.32M-0.30M-0.46M0.01M0.58M-0.24M-0.35M0.48M-0.12M-0.13M-0.15M0.00M0.49M0.01M-0.19M-0.22M-0.11M0.13M
Change in Account PayablesChange Payables
-0.26M0.96M0.87M0.72M1.10M-0.17M1.58M-2.61M-1.26M-0.97M-0.26M0.65M-0.74M1.48M0.72M-0.80M0.42M0.65M0.25M0.17M
Change in Accured ExpensesChange Accured Exp.
-1.65M-0.22M0.02M-0.10M0.02M0.06M0.08M-0.08M-0.06M1.15M-0.69M0.23M0.12M0.44M0.41M-0.41M0.18M0.54M0.19M0.56M
Change in Other Operating LiabilitiesOther Liabilities Change
0.01M0.14M-0.12M-0.50M-0.03M0.05M-0.08M-0.05M-0.06M0.34M0.00M0.00M0.03M0.03M0.00M0.06M0.01M0.01M0.08M0.06M
Other Working Capital ChangesOther WC Changes
0.01M0.14M-0.12M-0.50M-0.03M0.05M-0.08M-0.05M-0.06M0.34M0.00M0.00M0.03M0.03M0.00M0.06M0.01M0.01M0.08M0.06M
Cash from OperationsCash from Ops.
-6.46M-5.51M-3.69M-6.13M-4.85M-4.65M-3.99M-6.78M-6.41M-3.29M-3.06M-1.68M-3.30M-1.05M-1.63M-3.50M-1.10M-0.74M-1.32M-0.90M
Investing Activities
Capital ExpendituresCapex
0.24M0.04M0.01M0.02M0.00M0.02M
Change in Property, Plant and EquipmentChange in PP&E
-0.24M-0.04M-0.01M-0.02M0.00M-0.02M
Purchase of InvestmentsInvestments Purchased
Change in Acquisitions & DivestmentsChange Acquisitions
1.93M-1.26M-0.01M0.01M-0.01M1.04M2.01M0.00M0.01M0.20M
Other Investing ActivitiesOther investing
Cash from Investing ActivitiesCash from Investing
1.70M-1.30M-0.02M-0.01M-0.01M1.04M2.01M0.00M-0.01M0.20M
Financing Activities
Debt Issuance and Repayment
Short-Term Debt issuancesST Debt Issuance
0.90M-1.10M0.78M0.28M-0.13M
Current Debt
0.90M-1.10M0.78M0.28M-0.13M
Net Debt Issuances and RepaymentsNet Debt Issuance
0.90M-1.10M0.78M0.28M-0.13M
Change in Capital Stock
Common Stock IssuedStock Issued
-0.11M-0.03M3.23M5.30M7.10M3.35M2.54M4.37M1.06M2.19M3.35M0.31M0.00M0.97M1.02M
Net Shares Issued and RepurchasedNet Shares Issued
-0.11M-0.03M3.23M5.30M7.10M3.35M2.54M4.37M1.06M2.19M3.35M0.31M0.00M0.97M1.02M
Net Equity Issued and RepurchasedNet Equity Issued
-0.11M-0.03M3.23M5.30M7.10M3.35M2.54M4.37M1.06M2.19M3.35M0.31M0.00M0.97M1.02M
Other financing activitiesOther financing
Cash from Financing ActivitiesCash from Financing
-0.11M-0.03M3.23M5.30M7.10M3.35M2.54M4.37M1.06M3.09M2.70M0.31M0.78M1.25M0.90M
Additional items
Change in Cash
-4.87M-6.84M-3.71M-6.15M-4.86M-3.37M1.25M-1.48M0.68M0.26M-0.52M2.69M-3.30M0.02M1.46M-0.80M-0.79M0.04M-0.07M0.00M
Ending Cash Balance
25.70M18.86M15.15M9.01M4.14M0.77M2.02M0.55M1.22M1.49M0.96M3.65M0.35M0.37M1.83M1.03M0.24M0.28M0.21M0.21M
Free Cash FlowFCF
-6.70M-5.54M-3.70M-6.15M-4.85M-4.65M-3.99M-6.78M-6.43M-3.29M-3.06M-1.68M-3.30M-1.05M-1.63M-3.50M-1.10M-0.74M-1.32M-0.90M
Net Cash FlowNCF
-4.87M-6.84M-3.71M-6.15M-4.86M-3.61M1.25M-1.48M0.68M0.26M-0.52M2.69M-3.30M0.01M1.46M-0.80M-0.79M0.04M-0.07M0.00M

Brainstorm Cell Therapeutics Cash Flow Statement API

Pull Brainstorm Cell Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=BCLI&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY